By Disease
| Leukemia Products | Lymphoma Products | Other Diseases | ||
|
Invivoscribe's subsidiary, LabPMM, offers individual testing for both the FLT3 Mutation and the NPM1 Mutation Assays. Since results of both these tests are required to assess patient status and determine optimal care, they can be ordered together, as they are both members of the AML Mutation Panel, which tests both of these biomarkers. LabPMM is now the only reference laboratory outside Japan licensed to perform testing to determine FLT3 and NPM1 mutation status. |
Several of our LymphoTrack(TM) products are used to diagnose and monitor lymphomas. Our BCL1/JH Translocation Assay identifies presence of a t(11;14) gene translocation that is associated with Mantle Cell Lymphomas (MCL). Our LymphoTrack BCL2/JH Translocation Assay identifies t(14;18) gene translocations that are common in follicular lymphomas (FL). These CE-marked in vitro diagnostic products complement the number of other products that are used to differentiate between normal or benign processes and malignant or cancerous cell populations. |
Minimal residual disease (MRD) tests are highly sensitive patient-specific tests that target the antigen receptor genes. We design this test along with others to monitor patient therapy.
These tests quantify cancer cells in patients who have achieved remission. They provide "early warning” on cancer recurrence so a physician has time to intervene most effectively. |
By Gene or Biomarker
| Gene Rearrangement |
Gene Translocation |
Gene Mutation |
||
|
BCL1/JH |